1 Min Read
May 10 (Reuters) - Fate Therapeutics Inc
* Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 in advanced solid tumors Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.